LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders.
Flawless balance sheet with limited growth.
Share Price & News
How has LifeTech Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 1302's share price has been volatile over the past 3 months.
7 Day Return
HK Medical Equipment
1 Year Return
HK Medical Equipment
Return vs Industry: 1302 underperformed the Hong Kong Medical Equipment industry which returned 222.6% over the past year.
Return vs Market: 1302 exceeded the Hong Kong Market which returned 6% over the past year.
Price Volatility Vs. Market
How volatile is LifeTech Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWhat You Need To Know About LifeTech Scientific Corporation's (HKG:1302) Investor Composition
4 weeks ago | Simply Wall StLifeTech Scientific Corporation's (HKG:1302) Price In Tune With Earnings
1 month ago | Simply Wall StA Look At The Fair Value Of LifeTech Scientific Corporation (HKG:1302)
Is LifeTech Scientific undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 1302 (HK$2.26) is trading above our estimate of fair value (HK$2.14)
Significantly Below Fair Value: 1302 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 1302 is poor value based on its PE Ratio (65.2x) compared to the HK Medical Equipment industry average (50.8x).
PE vs Market: 1302 is poor value based on its PE Ratio (65.2x) compared to the Hong Kong market (10.4x).
Price to Earnings Growth Ratio
PEG Ratio: 1302 is poor value based on its PEG Ratio (4.1x)
Price to Book Ratio
PB vs Industry: 1302 is overvalued based on its PB Ratio (7.6x) compared to the HK Medical Equipment industry average (4.1x).
How is LifeTech Scientific forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1302's forecast earnings growth (15.7% per year) is above the savings rate (1.6%).
Earnings vs Market: 1302's earnings (15.7% per year) are forecast to grow slower than the Hong Kong market (18.2% per year).
High Growth Earnings: 1302's earnings are forecast to grow, but not significantly.
Revenue vs Market: 1302's revenue (19.9% per year) is forecast to grow faster than the Hong Kong market (11.3% per year).
High Growth Revenue: 1302's revenue (19.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1302's Return on Equity is forecast to be low in 3 years time (14%).
How has LifeTech Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1302 has high quality earnings.
Growing Profit Margin: 1302's current net profit margins (19.3%) are lower than last year (21.8%).
Past Earnings Growth Analysis
Earnings Trend: 1302 has become profitable over the past 5 years, growing earnings by 28.7% per year.
Accelerating Growth: 1302's earnings growth over the past year (6.7%) is below its 5-year average (28.7% per year).
Earnings vs Industry: 1302 earnings growth over the past year (6.7%) underperformed the Medical Equipment industry 16%.
Return on Equity
High ROE: 1302's Return on Equity (10.9%) is considered low.
How is LifeTech Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: 1302's short term assets (CN¥605.8M) exceed its short term liabilities (CN¥341.2M).
Long Term Liabilities: 1302's short term assets (CN¥605.8M) exceed its long term liabilities (CN¥269.3M).
Debt to Equity History and Analysis
Debt Level: 1302's debt to equity ratio (28.4%) is considered satisfactory.
Reducing Debt: 1302's debt to equity ratio has reduced from 51% to 28.4% over the past 5 years.
Debt Coverage: 1302's debt is well covered by operating cash flow (83.3%).
Interest Coverage: 1302's interest payments on its debt are well covered by EBIT (10.3x coverage).
What is LifeTech Scientific current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1302's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1302's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1302's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1302's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: 1302 is not paying a notable dividend for the Hong Kong market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1302's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yuehui Xie (51 yo)
Mr. Yuehui Xie has been the Chief Executive Officer at LifeTech Scientific Corporation since March 2, 2015. Mr. Xie is responsible for overall strategic planning and management of LifeTech Scientific Corpo ...
CEO Compensation Analysis
Compensation vs Market: Yuehui's total compensation ($USD2.33M) is above average for companies of similar size in the Hong Kong market ($USD565.26K).
Compensation vs Earnings: Yuehui's compensation has been consistent with company performance over the past year.
|Chairman & CEO||5.42yrs||CN¥16.25m||18.07% |
|CFO, Executive VP||5.42yrs||CN¥12.99m||0.19% |
|Independent Non-Executive Director||8.83yrs||CN¥108.00k||no data|
|Independent Non-Executive Director||6.33yrs||CN¥108.00k||no data|
|Non-Executive Director||6.33yrs||CN¥108.00k||no data|
|Independent Non-Executive Director||4.58yrs||CN¥108.00k||no data|
|Non-Executive Director||1yr||no data||no data|
Experienced Board: 1302's board of directors are considered experienced (5.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
LifeTech Scientific Corporation's company bio, employee growth, exchange listings and data sources
- Name: LifeTech Scientific Corporation
- Ticker: 1302
- Exchange: SEHK
- Founded: 1999
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: HK$9.690b
- Shares outstanding: 4.33b
- Website: https://www.lifetechmed.com
Number of Employees
- LifeTech Scientific Corporation
- Cybio Electronic Building
- Langshan 2nd Street
- Guangdong Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|1302||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Common Shares||HK||HKD||Nov 2011|
|1302||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Common Shares||HK||HKD||Nov 2011|
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The c ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/05 13:08|
|End of Day Share Price||2020/08/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.